{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:07:05Z","timestamp":1790665625502,"version":"4.1.0"},"reference-count":73,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The typical genome of chronic lymphocytic leukemia (CLL) carries \u223c2000 molecular lesions. Few mutations recur across patients at a frequency &gt;5%, whereas a large number of biologically and clinically uncharacterized genes are mutated at lower frequency. Approximately 80% of CLL patients carry at least 1 of 4 common chromosomal alterations, namely deletion 13q14, deletion 11q22-23, deletion 17p12, and trisomy 12. Knowledge of the CLL genome has translated into the availability of molecular biomarkers for prognosis and treatment prediction. Prognostic biomarkers do not affect treatment choice, and can be integrated into prognostic scores that are based on both clinical and biological variables. Molecular predictive biomarkers affect treatment choice, and currently include TP53 disruption by mutation and\/or deletion and IGHV mutation status. TP53 disruption by gene mutation and\/or deletion associates with chemoimmunotherapy failure and mandates treatment with innovative drugs, including ibrutinib, idelalisib, or venetoclax. The mutation status of IGHV genes represents a predictive biomarker for identifying patients that may benefit the most from chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. Assessment of these biomarkers at the time of treatment requirement is recommended by most current guidelines for CLL management. Other molecular predictors are under investigation, but their application in clinical practice is premature.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.329","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"329-337","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment"],"prefix":"10.1182","volume":"2017","author":[{"given":"Gianluca","family":"Gaidano","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and"},{"name":"Institute of Oncology Research, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7574","key":"2019111703225355800_B1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"7574","key":"2019111703225355800_B2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"issue":"26","key":"2019111703225355800_B3","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111703225355800_B4","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111703225355800_B5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ccr.2009.11.019","article-title":"The DLEU2\/miR-15a\/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia","volume":"17","author":"Klein","year":"2010","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111703225355800_B6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111703225355800_B7","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1158\/0008-5472.CAN-14-0630","article-title":"Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution","volume":"74","author":"Vardi","year":"2014","journal-title":"Cancer Res"},{"issue":"33","key":"2019111703225355800_B8","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111703225355800_B9","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1200\/JCO.2015.66.3815","article-title":"Is it time to redefine prognostic and predictive in oncology?","volume":"34","author":"Minden","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111703225355800_B10","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"6","key":"2019111703225355800_B11","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"6","key":"2019111703225355800_B12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2141.2009.07699.x","article-title":"Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate","volume":"145","author":"Delgado","year":"2009","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111703225355800_B13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/gcc.20794","article-title":"Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters","volume":"49","author":"Haferlach","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"issue":"20","key":"2019111703225355800_B14","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1002\/cncr.25292","article-title":"Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia","volume":"116","author":"Shanafelt","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"2019111703225355800_B15","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3324\/haematol.2010.039396","article-title":"LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia","volume":"96","author":"Kaderi","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"2019111703225355800_B16","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2010-12-327858","article-title":"Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia","volume":"118","author":"Ouillette","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111703225355800_B17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clml.2012.01.009","article-title":"IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia","volume":"12","author":"Cahill","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2019111703225355800_B18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2141.2011.08974.x","article-title":"Defining the prognosis of early stage chronic lymphocytic leukaemia patients","volume":"156","author":"Pepper","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111703225355800_B19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111703225355800_B20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/gcc.22028","article-title":"Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia","volume":"52","author":"Lech-Maranda","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2019111703225355800_B21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/leu.2012.307","article-title":"NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia","volume":"27","author":"Mansouri","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"2019111703225355800_B22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ajh.23466","article-title":"Short telomere length is associated with NOTCH1\/SF3B1\/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients","volume":"88","author":"Mansouri","year":"2013","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111703225355800_B23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/leu.2013.333","article-title":"On the way towards a \u2018CLL prognostic index\u2019: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort","volume":"28","author":"Cortese","year":"2014","journal-title":"Leukemia"},{"key":"2019111703225355800_B24","volume-title":"BioMed Res Int","author":"Gonz\u00e1lez-Gasc\u00f3n","year":"2014"},{"issue":"5","key":"2019111703225355800_B25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/bjh.12800","article-title":"High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications","volume":"165","author":"Lionetti","year":"2014","journal-title":"Br J Haematol"},{"issue":"14","key":"2019111703225355800_B26","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111703225355800_B27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI Working Group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"2019111703225355800_B28","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111703225355800_B29","first-page":"238","article-title":"Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia","volume":"127","author":"Putowski","year":"2017","journal-title":"Pol Arch Intern Med"},{"issue":"14","key":"2019111703225355800_B30","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood-2015-10-620864","article-title":"Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis","volume":"127","author":"Parikh","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111703225355800_B31","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111703225355800_B32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2011","journal-title":"Nat Genet"},{"issue":"3","key":"2019111703225355800_B33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.12128","article-title":"Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukemia","volume":"160","author":"Del Poeta","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111703225355800_B34","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"2019111703225355800_B35","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/leu.2013.218","article-title":"Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients","volume":"27","author":"Weissmann","year":"2013","journal-title":"Leukemia"},{"key":"2019111703225355800_B36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/1471-2407-13-274","article-title":"NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients","volume":"13","author":"Willander","year":"2013","journal-title":"BMC Cancer"},{"issue":"1","key":"2019111703225355800_B37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/leu.2013.263","article-title":"SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients","volume":"28","author":"Jeromin","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2019111703225355800_B38","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/leu.2013.289","article-title":"A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia","volume":"28","author":"Sportoletti","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2019111703225355800_B39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/leu.2014.196","article-title":"Recurrent mutations refine prognosis in chronic lymphocytic leukemia","volume":"29","author":"Baliakas","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"2019111703225355800_B40","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.3324\/haematol.2015.136051","article-title":"Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia","volume":"101","author":"Rasi","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"2019111703225355800_B41","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.3324\/haematol.2016.154450","article-title":"Integration of B-cell receptor-induced ERK1\/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-na\u00efve chronic lymphocytic leukemia","volume":"102","author":"Cavallini","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"2019111703225355800_B42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111703225355800_B43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.833.833","article-title":"Outcome of ibrutinib treatment by baseline genetic features in patients with relapsed or refractory CLL\/SLL with del17p in the Resonate-17 study [abstract]","volume":"126","author":"Stilgenbauer","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111703225355800_B44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1632.1632","article-title":"Clinical activity of idelalisib (GS-1101), a selective inhibitor of PI3K\u03b4, in phase 1 and 2 trials in chronic lymphocytic leukemia (CLL): effect of del(17p)\/TP53 mutation, del(11q), IGHV mutation, and NOTCH1 mutation [abstract]","volume":"122","author":"Coutre","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111703225355800_B45","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2019111703225355800_B46","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111703225355800_B47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.seminoncol.2016.02.002","article-title":"Gene mutations in chronic lymphocytic leukemia","volume":"43","author":"Amin","year":"2016","journal-title":"Semin Oncol"},{"issue":"22","key":"2019111703225355800_B48","article-title":"Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"128","author":"O\u2019Brien","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111703225355800_B49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111703225355800_B50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.12550","article-title":"Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model","volume":"96","author":"Molica","year":"2016","journal-title":"Eur J Haematol"},{"issue":"16","key":"2019111703225355800_B51","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2016-07-728261","article-title":"Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients","volume":"128","author":"Gentile","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2019111703225355800_B52","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood-2016-07-724740","article-title":"The CLL-IPI applied in a population-based cohort","volume":"128","author":"da Cunha-Bang","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111703225355800_B53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.24660","article-title":"Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI","volume":"92","author":"Delgado","year":"2017","journal-title":"Am J Hematol"},{"issue":"16","key":"2019111703225355800_B54","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111703225355800_B55","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111703225355800_B56","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2019111703225355800_B57","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"9747","key":"2019111703225355800_B58","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"26","key":"2019111703225355800_B59","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111703225355800_B60","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"9980","key":"2019111703225355800_B61","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"2019111703225355800_B62","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111703225355800_B63","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111703225355800_B64","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111703225355800_B65","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O\u2019Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111703225355800_B66","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111703225355800_B67","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.527.527","article-title":"NOTCH1 mutation and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-Chl (O-Chl): results from the phase III study complement 1 (OMB110911) [abstract]","volume":"122","author":"Tausch","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2019111703225355800_B68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3227.3227","article-title":"Gene mutations and treatment outcome in the context of chlorambucil (Clb) without or with the addition of rituximab (R) or obinutuzumab (GA-101, G): results of an extensive analysis of the phase III study CLL11 of the German CLL Study Group [abstract]","volume":"128","author":"Estenfelder","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2019111703225355800_B69","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2019111703225355800_B70","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"2019111703225355800_B71","doi-asserted-by":"crossref","first-page":"326","DOI":"10.6004\/jnccn.2015.0045","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 1.2015","volume":"13","author":"Zelenetz","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"2019111703225355800_B72","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/leu.2017.125","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations","volume":"31","author":"Rosenquist","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2019111703225355800_B73","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3324\/haematol.2015.139246","article-title":"Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?","volume":"101","author":"Pospisilova","year":"2016","journal-title":"Haematologica"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/329\/1250189\/hem00046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/329\/1250189\/hem00046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T19:32:43Z","timestamp":1721158363000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/329\/21128\/The-mutational-landscape-of-chronic-lymphocytic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.329","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}